# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-21-136301
Filing Date
2021-11-09
Accepted
2021-11-09 16:30:44
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | tm2132349d1_defa14a.htm | DEFA14A | 15256
2 | GRAPHIC | tm2132349d1_defa14aimg001.jpg | GRAPHIC | 474500
3 | GRAPHIC | tm2132349d1_defa14aimg002.jpg | GRAPHIC | 506632
| Complete submission text file | 0001104659-21-136301.txt |  | 1368112

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33357 | Film No.: 211392707
SIC: 2836 Biological Products, (No Diagnostic Substances)